Scopus:
Pharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous

dc.contributor.authorAltan F.
dc.contributor.authorCorum O.
dc.contributor.authorCorum D.D.
dc.contributor.authorAtik O.
dc.contributor.authorUney K.
dc.date.accessioned2023-04-12T02:15:22Z
dc.date.available2023-04-12T02:15:22Z
dc.date.issued2018-02-01
dc.description.abstractIn this study, the pharmacokinetic disposition and bioavailability of marbofloxacin (MB) were determined in lambs after single intravenous (IV), intramuscular (IM), and subcutaneous (SC) administrations at a dose of 3 mg/kg. The plasma concentration of MB was measured using high-performance liquid chromatography-UV, and the pharmacokinetic parameters were analyzed using a non-compartmental analysis. Following IV, IM, and SC administrations, the mean terminal half-life (t1/2ʎz) was 11.48, 12.64, and 24.86 h, respectively, and the mean residence time (MRT) was 7.27, 7.81, and 10.11 h, respectively. The bioavailability (F) was 96.01 and 126.39%, after IM and SC administration, respectively. This study showed that SC administration of MB at a dose of 3 mg/kg exhibited flip-flop pharmacokinetics in lambs. These results suggested that MB could be useful in the treatment of severe systemic infections, such as those with M. haemolytica (MIC = 0.035 μg/mL), in lambs since high AUC0-24/MIC and Cmax/MIC ratios were achieved after IV and IM administration at 3 mg/kg. However, MB administration (3 mg/kg) via the IV, IM, and SC routes might not be effective in the treatment of respiratory infections caused by organisms with MIC90 value in lambs.
dc.identifier.doi10.1016/j.smallrumres.2017.12.004
dc.identifier.issn09214488
dc.identifier.scopus2-s2.0-85037992216
dc.identifier.urihttps://hdl.handle.net/20.500.12597/5330
dc.relation.ispartofSmall Ruminant Research
dc.rightsfalse
dc.subjectFluoroquinolones | Lamb | Marbofloxacin | Pharmacokinetics
dc.titlePharmacokinetics and bioavailability of marbofloxacin in lambs following administration of intravenous, intramuscular and subcutaneous
dc.typeArticle
dspace.entity.typeScopus
oaire.citation.volume159
person.affiliation.nameDicle Üniversitesi
person.affiliation.nameKastamonu University
person.affiliation.nameKastamonu University
person.affiliation.nameSelçuk Üniversitesi
person.affiliation.nameSelçuk Üniversitesi
person.identifier.scopus-author-id26433107400
person.identifier.scopus-author-id55902904600
person.identifier.scopus-author-id57204288970
person.identifier.scopus-author-id57199403375
person.identifier.scopus-author-id8408064700
relation.isPublicationOfScopus4c5136e2-fe2f-4a8d-8559-e88a3cf487db
relation.isPublicationOfScopus.latestForDiscovery4c5136e2-fe2f-4a8d-8559-e88a3cf487db

Files